Breaking News

Anavex Secures cGMP Manufacture for ANAVEX Trials

July 21, 2014

Phase IIa trial scheduled for 2014

Anavex Life Sciences Corp. has secured cGMP manufacture of ANAVEX 2-73 for its clinical trial supplies. Further details were not disclosed.
 
"We are delighted to have the active drug product (API) manufactured and available for our Phase IIa trial," said Christopher U. Missling, PhD, president and chief executive officer of Anavex. "We look forward to initiating clinical trials with ANAVEX PLUS for the treatment of Alzheimer's disease, which remains on track to commence in 2014 with data from the first part of the trial expected to be reported in mid 2015.”

blog comments powered by Disqus
  • CMC Biologics: Growing Through Innovation

    Tim Wright, Editor||January 28, 2016
    The new chief exec talks about industry trends and growth plans.

  • Cold-Chain Logistics & The Central Lab

    Kristin Brooks, Associate Editor||January 28, 2016
    Eric Hayashi of LabConnect discusses safety measures to ensure sample integrity

  • A Look at DCAT Week ‘16

    Tim Wright, Editor||January 28, 2016
    On the pulse of the pharmaceutical manufacturing value chain, DCAT Week ‘16 will deliver top-flight education programs and networking events.